Niemeyer: API Innovation Center created the NFI to become a more complete understanding of pharmaceutical supply chain risk. It helps us establish a data-driven benchmark for measuring systematic fragility across US pharmaceutical supply chains , as well as others. Becoming data-driven, to decrease the probability of supply chain disruptions, will become a highly effective tool for various organizations, regardless of where you might touch the supply chain. If price is no longer the only factor, does scoring supply chain risk create any incentive for domestic manufacturing investment, or does it take policy mandates to move that needle? When you take that back through the graph of the supply chain, the amount of moving pieces is immense.